Amprologix
Amprologix is a biotechnology company founded in 2018 in collaboration with the University of Plymouth, pioneering a drug discovery program focused on developing a new class of antibiotics to combat antimicrobial resistance (AMR). Their lead product, NI01, is a potent bactericidal peptide designed for topical use, particularly targeting MRSA nasal decolonization, bacterial pneumonia, and skin infections. The company leverages artificial intelligence and machine learning in partnership with STFC to accelerate antibiotic discovery and optimize drug properties. Amprologix has progressed through preclinical and early clinical stages, securing significant funding and partnerships, including manufacturing with Ingenza LTD. Their pipeline includes a family of novel therapeutics derived from NI01 with broad antibacterial activity and no known resistance liabilities, positioning them strongly in the urgent global market for new antibiotics against WHO priority pathogens.
Amprologix
Amprologix is a biotechnology company founded in 2018 in collaboration with the University of Plymouth, pioneering a drug discovery program focused on developing a new class of antibiotics to combat antimicrobial resistance (AMR). Their lead product, NI01, is a potent bactericidal peptide designed for topical use, particularly targeting MRSA nasal decolonization, bacterial pneumonia, and skin infections. The company leverages artificial intelligence and machine learning in partnership with STFC to accelerate antibiotic discovery and optimize drug properties. Amprologix has progressed through preclinical and early clinical stages, securing significant funding and partnerships, including manufacturing with Ingenza LTD. Their pipeline includes a family of novel therapeutics derived from NI01 with broad antibacterial activity and no known resistance liabilities, positioning them strongly in the urgent global market for new antibiotics against WHO priority pathogens.